Literature summary for 2.7.11.1 extracted from

Oh, Y.; Herbst, R.S.; Burris, H.; Cleverly, A.; Musib, L.; Lahn, M.; Bepler, G.
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer (2008), J. Clin. Oncol., 26, 1135-1141.

Search for more literature for 2.7.11.1

Application

Application	Comment	Organism
medicine	a phase II trial of enzastaurin is conducted to determine the 6-month progression-free survival rate in advanced non-small-cell lung cancer using Enzaustaurin: 13% of the patients have a progression-free survival for more than 6 months	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
enzastaurin	oral serine/threonine kinase inhibitor	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Synonyms

Synonyms	Comment	Organism
p-AKT	-	Homo sapiens
protein kinase C	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)